R&D Trends

Lupus Research Institute launches global research initiative

Monday, October 17, 2011 12:36 PM

The Lupus Research Institute (LRI) has launched a major international initiative aimed at attracting the highest level scientists to conduct pioneering research to discover the fundamental root causes of lupus, explore the potential for a cure, and transform the field of lupus research.

More... »

deCODE, Pfizer ink research agreement

Thursday, October 13, 2011 10:45 AM

deCODE genetics has entered into a research collaboration with Pfizer to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis.

More... »

Exonhit, Pfizer collaborate in Alzheimer’s research

Tuesday, October 11, 2011 02:26 PM

Exonhit has entered into a research agreement with Pfizer for the identification of new Alzheimer's disease biomarkers using Exonhit's Genome-Wide SpliceArray (GWSA) platform.

More... »

Researchers use RNA technology to block inflammation

Tuesday, October 11, 2011 01:26 PM

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage.

More... »

MediSapiens, Bayer HealthCare collaborate in oncology

Tuesday, October 11, 2011 01:01 PM

MediSapiens and Bayer HealthCare Pharmaceuticals have agreed to develop a platform for genomics data management and analysis in oncology.

More... »

Hybrigenics, Servier ink license and research agreement

Tuesday, October 11, 2011 11:38 AM

Hybrigenics and Servier have signed a license and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.

More... »

Sponsors using partnerships to speed development

Tuesday, October 11, 2011 11:14 AM

Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative partnerships that are leading to, among other things, more molecular entities entering phase I trials and shorter study times, according to a panel of leaders from the drug research industry recently convened by the Tufts Center for the Study of Drug Development.

More... »

NIHR launches first two translational partnerships in U.K.

Tuesday, October 11, 2011 10:38 AM

NIHR translational research partnerships bring together investigators at the U.K.’s leading academic and NHS centers to support collaboration with the life sciences industry in early and exploratory development of new drugs and other interventions.

More... »

Massachusetts leads U.S. in biotech R&D jobs

Monday, October 10, 2011 08:00 AM

Though it may be small, the state of Massachusetts continues to lead the U.S. in biotechnology research and development jobs, with 26,807 such positions. And companies in the state garnered almost a quarter of all venture capital flowing into the sector nationally, an all-time high share for Massachusetts. And the pace of employment growth in the overall biopharma industry is second only to much larger California.

More... »

Report: U.S. medical innovation at risk without funding

Thursday, October 6, 2011 12:03 PM

U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investment away from the United States towards Europe and Asia, according to a report by the National Venture Capital Association'sMedIC Coalition.

More... »